ONC Stock - BeOne Medicines Ltd.
Unlock GoAI Insights for ONC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.81B | $2.46B | $1.42B | $1.18B | $308.87M |
| Gross Profit | $3.22B | $2.08B | $1.13B | $1.01B | $238.22M |
| Gross Margin | 84.4% | 84.5% | 79.8% | 86.0% | 77.1% |
| Operating Income | $-568,199,000 | $-1,207,736,000 | $-1,789,665,000 | $-1,438,735,000 | $-1,657,682,000 |
| Net Income | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 | $-1,624,974,000 |
| Net Margin | -16.9% | -35.9% | -141.5% | -123.9% | -526.1% |
| EPS | $-6.12 | $-8.45 | $-19.37 | $-15.21 | $-19.11 |
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Visit WebsiteEarnings History & Surprises
ONCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $1.71 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.72 | $1.09 | +51.4% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.48 | $0.84 | +75.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.71 | $1.22 | +271.8% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.88 | $-1.43 | -62.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.88 | $-1.15 | -30.7% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-2.10 | $-1.15 | +45.2% | ✓ BEAT |
Q1 2024 | Mar 31, 2024 | — | $-2.41 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-25.53 | — | — |
Q3 2023 | Sep 30, 2023 | — | $2.01 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-3.64 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-3.34 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-30.54 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-5.39 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-5.56 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-4.24 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-6.16 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-4.46 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-5.23 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.69 | — | — |
Latest News
Frequently Asked Questions about ONC
What is ONC's current stock price?
What is the analyst price target for ONC?
What sector is BeOne Medicines Ltd. in?
What is ONC's market cap?
Does ONC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ONC for comparison